Duopharma Biotech Bhd

Duopharma Biotech Bhd EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Duopharma Biotech Bhd (DPHARMA.KL) as of Nov 15, 2026 is 33.82. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 183.96 — a change of -81.62% (lower).

EV/FCF

33.82

YoY

-81.62%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Duopharma Biotech Bhd is 2024 33.82 . EV/FCF (Enterprise Value to Free Cash Flow) of Duopharma Biotech Bhd was 2023 183.96 . It decreases by -81.62% lower compared to the previous year.

The Duopharma Biotech Bhd EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2017
-78.48 MYR
Jan 1, 2018
-76.83 MYR
Jan 1, 2019
258.44 MYR
Jan 1, 2020
273.72 MYR
Jan 1, 2021
-23.50 MYR
Jan 1, 2022
-2,243.02 MYR
Jan 1, 2023
183.96 MYR
Jan 1, 2024
33.82 MYR
The Duopharma Biotech Bhd EV/FCF history
YEAREV/FCFYoY
33.82-81.62%
183.96-108.20%
-2,243.02+9,446.38%
-23.50-108.58%
273.72+5.92%
258.44-436.36%
-76.83-2.10%
-78.48-92.04%
-986.24+6,388.10%
-15.20-125.47%
59.69—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Duopharma Biotech Bhd Stock analysis

What does Duopharma Biotech Bhd do? Duopharma Biotech Bhd generates revenue through its three business segments: Consumer Healthcare (CHC), Ethical Classic Business (ECB), and Ethical Specialty Business (ESB). The CHC segment sells over-the-counter products like vitamins, supplements, analgesics, eyecare, and antacids under brands such as Flavettes, CHAMPS, Uphamol, and Eye Glo to domestic, regional, and international markets. The ECB segment produces over 300 generic drugs including Crystorvas, Prelica, and Omesec, targeting healthcare providers and pharmacies. The ESB segment focuses on specialized drugs, medical devices, and consumables, while also commercializing biosimilars like ERYSAA, Basalog One, and Zuhera through international partnerships. The company's products are distributed across multiple markets, with CHC brands reaching consumers directly through retail channels. ECB drugs are supplied to healthcare institutions and pharmacies, while ESB products target specialized medical needs. Biosimilar collaborations with international partners enable the company to expand its portfolio beyond traditional pharmaceuticals, enhancing its market presence in both domestic and global segments. Duopharma Biotech Bhd's revenue streams are diversified across consumer-facing CHC products, generic ECB drugs, and specialized ESB solutions. The company leverages its established brands and partnerships to serve both mass-market and niche healthcare segments, ensuring steady demand for its pharmaceutical offerings in Malaysia and beyond. Duopharma Biotech Bhd is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Duopharma Biotech Bhd stock

EV/FCF (Enterprise Value to Free Cash Flow) of Duopharma Biotech Bhd is 33.82 in 2024.

EV/FCF (Enterprise Value to Free Cash Flow) of Duopharma Biotech Bhd changed from 183.96 to 33.82, representing a -81.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Duopharma Biotech Bhd since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Duopharma Biotech Bhd with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Duopharma Biotech Bhd

All Key Metrics — Duopharma Biotech Bhd